This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Revance Therapeutics faces securities lawsuit
Business class action lawsuit

Revance Therapeutics faces securities lawsuit

Analysis based on 10 articles · First reported Feb 07, 2025 · Last updated Feb 21, 2025

Sentiment
-50
Attention
2
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Revance Therapeutics is likely to negatively impact its stock price and investor confidence due to allegations of securities fraud and potential monetary and reputational harm. This event highlights the risks associated with corporate disclosures and compliance with distribution agreements in the biotechnology industry.

Biotechnology Legal Services
Event Summary

Levi & Korsinsky has notified investors of a class action securities lawsuit against Revance Therapeutics. The lawsuit alleges that Revance Therapeutics made false and misleading statements and/or concealed material information between February 29, 2024, and December 6, 2024. Specifically, it claims that Revance Therapeutics was in material breach of its Distribution Agreement with Teoxane, which granted Revance Therapeutics the exclusive right to import, market, promote, sell, and distribute Teoxane's line of dermal fillers. These alleged actions subjected Revance Therapeutics to increased risks of litigation, monetary, and reputational harm, and potentially delayed or amended a tender offer. Investors who suffered losses during the specified period have until March 4, 2025, to request to be appointed as lead plaintiff.

Key Actions
100 Levi & Korsinsky filed class action lawsuit Revance Therapeutics
90 Revance Therapeutics made false statements
90 Revance Therapeutics concealed material breach Teoxane
Entities Involved
stock
Revance Therapeutics
Revance Therapeutics is the defendant in a class action securities lawsuit, facing allegations of making false and misleading statements regarding a material breach of its Distribution Agreement with Teoxane, which could lead to significant financial and reputational harm.
Importance 100.0 Sentiment -70.0
priv
Teoxane
Revance Therapeutics is alleged to have been in material breach of its Distribution Agreement with Teoxane, which granted Revance Therapeutics exclusive rights to distribute Teoxane's dermal fillers.
Importance 40.0 Sentiment 0.0
priv
Levi & Korsinsky
Importance 0.0 Sentiment 0.0
per
Joseph E. Levi
Importance 0.0 Sentiment 0.0
Relationships
Levi & Korsinsky related ↔ Joseph E. Levi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.